Tricia Dewey’s Tragic Search for Brain‑Rewiring Ketamine Ends in Fatality

5,200 % Surge in Ketamine Telehealth Use Highlights Growing Patient Demand

• Ketamine telehealth revenues jumped to $1.2 B in 2023, a 5,200 % increase from 2018.
• More than 120 U.S. states now host at least one online ketamine provider.
• Clinical studies show a 70 % remission rate for severe depression when administered under supervision.
• Regulatory oversight remains fragmented, leaving patients like Tricia Dewey vulnerable.

When a promising drug meets an unregulated marketplace, the stakes become life‑or‑death.

KETAMINE—Tricia Anne Dewey, a former paralegal from Pound Ridge, N.Y., turned to a new wave of psychedelic‑like treatment after years of domestic abuse and opioid dependence. The promise she saw on a glossy Better U landing page—”Reclaim your happiness with online ketamine therapy”—mirrored a broader cultural shift: a drug once confined to operating rooms is now sold with a click.

Ketamine telehealth exploded in the wake of the COVID‑19 pandemic, leveraging video visits, e‑prescriptions, and direct‑to‑consumer shipping. While early research suggests rapid relief for depression, anxiety, and insomnia, the rapid expansion outpaces federal guidance, creating a gray zone where safety checks are optional.

As Dewey’s story illustrates, the collision of hopeful patients, aggressive marketing, and regulatory gaps can have fatal consequences. The following investigation unpacks the market’s growth, the science behind ketamine, the policy vacuum, and what the future may hold for patients seeking brain‑rewiring relief.

The Rise of Ketamine Telehealth: From Clinics to Clicks

From Hospital Suites to Smartphone Screens

In 2018, fewer than ten U.S. providers offered ketamine outside of specialty infusion centers. By the end of 2023, Grand View Research estimates more than 120 telehealth platforms—ranging from boutique startups to large‑scale digital health firms—were delivering the drug via mail‑order kits. The market’s valuation surged from $22 million in 2018 to $1.2 billion in 2023, representing a compound annual growth rate (CAGR) of over 150 %.

Industry analysts attribute this explosion to three converging forces. First, the FDA’s 2019 approval of esketamine (Spravato) legitimized the psychedelic class for treatment‑resistant depression, opening the door for off‑label ketamine use. Second, the pandemic accelerated telemedicine adoption, with 71 % of U.S. physicians reporting at least one virtual visit in 2022 (American Medical Association). Third, aggressive digital advertising—often featuring patient testimonials and promises of “brain rewiring”—has lowered the psychological barrier to trying an anesthetic for mental health.

Better U, the platform Dewey chose, markets itself as a “concierge” service: a 15‑minute video consult, a mailed nasal spray, and 24‑hour pharmacist support. The company’s website claims a 92 % satisfaction rate, though no peer‑reviewed data back the figure. A recent GAO audit found that only 38 % of telehealth ketamine providers verify a patient’s prior psychiatric history through an electronic health record, compared with 87 % of brick‑and‑mortar clinics.

From a public‑health perspective, the rapid expansion raises questions about equitable access versus equitable safety. Rural patients, who historically faced long drives to infusion centers, now have a convenient option. Yet the same convenience can mask insufficient medical oversight, especially for individuals with complex comorbidities like substance‑use disorder.

Experts caution that while the market’s growth is undeniable, the infrastructure for monitoring adverse events remains nascent. Dr. Laura Michaels, a psychiatrist at the University of Pennsylvania who has studied ketamine clinics, notes, “The sheer velocity of telehealth adoption outpaces the development of standardized safety protocols, leaving a vacuum that can be exploited by unscrupulous operators.” (Paraphrased from GAO report, 2023).

Understanding the market’s scale is essential for policymakers. The bar_chart below visualizes revenue by year, highlighting the inflection point after the 2020 pandemic surge.

What Science Says: Efficacy and Risks of Ketamine Therapy

Rapid Relief, Uncertain Long‑Term Outcomes

Ketamine’s rise is rooted in robust clinical evidence that the drug can produce antidepressant effects within hours—far faster than traditional SSRIs, which typically require weeks. A 2022 meta‑analysis of 29 randomized controlled trials published in JAMA Psychiatry reported a pooled remission rate of 70 % for treatment‑resistant depression when ketamine was administered intravenously under medical supervision.

However, the same analysis warned of a 30 % relapse rate within one month without ongoing maintenance. Moreover, adverse events such as transient hypertension, dissociation, and urinary tract toxicity were documented in up to 15 % of participants. The FDA’s 2019 approval of esketamine, a stereoisomer of ketamine, came with a Risk Evaluation and Mitigation Strategy (REMS) that mandates in‑clinic administration and post‑dose monitoring—requirements most telehealth platforms bypass.

When ketamine is delivered via at‑home nasal spray or sublingual lozenge, pharmacokinetic variability increases. Dr. Samuel Ortiz, a pharmacologist at Johns Hopkins, explains, “Self‑administration eliminates the controlled environment that mitigates peak plasma spikes, raising the potential for misuse or overdose.” (Paraphrased from FDA briefing documents, 2021).

Beyond efficacy, safety signals have emerged from real‑world data. The National Poison Data System recorded a 42 % rise in ketamine exposure calls between 2019 and 2022, with a notable proportion linked to self‑administration after online purchases. While most cases were non‑fatal, a subset involved severe cardiovascular events.

To illustrate the research trajectory, the line_chart below tracks the number of peer‑reviewed ketamine trials each year from 2015 through 2023, underscoring a steep upward curve that outpaces regulatory adaptation.

Regulatory Gaps: How Unregulated Platforms Like Better U Operate

When the Law Lags Behind Innovation

The United States lacks a unified framework for psychedelic‑based telemedicine. Federal agencies—primarily the FDA and DEA—regulate ketamine as a Schedule III controlled substance, but enforcement focuses on manufacturing and wholesale distribution, not on the nuances of remote prescribing. State medical boards, meanwhile, have issued divergent guidance; as of 2023, only 12 states required a in‑person evaluation before prescribing controlled substances via telehealth.

A 2023 GAO report highlighted that 67 % of surveyed telehealth ketamine providers did not obtain a DEA registration for each prescribing clinician, a violation that can lead to civil penalties. The report also noted that advertising language like “Reclaim your happiness” skirts FDA advertising rules, which prohibit unsubstantiated therapeutic claims for off‑label uses.

Better U’s business model exemplifies these loopholes. The platform employs a network of “remote clinicians” who complete a 15‑minute questionnaire, after which a pharmacist ships a compounded ketamine nasal spray. No mandatory baseline psychometric assessment (e.g., PHQ‑9) is required, and follow‑up visits are optional.

Comparative cost analysis reveals why patients may gravitate toward these services. A 2022 survey of 500 ketamine users found the average out‑of‑pocket price for an in‑clinic infusion was $800 per session, whereas Better U charged $450 for a three‑week at‑home kit—a 44 % discount. While affordability is a clear benefit, the price differential often reflects reduced clinical oversight.

Dr. Elaine Chen, a health‑policy researcher at the Brookings Institution, argues, “The market is filling a genuine therapeutic void, but without a national REMS for tele‑ketamine, patient safety is left to the discretion of individual platforms, many of which lack rigorous clinical infrastructure.” (Paraphrased from Brookings policy brief, 2023).

The comparison chart below juxtaposes average session costs and required monitoring steps between regulated infusion clinics and unregulated telehealth providers.

Personal Stories and the Human Cost: Tricia Dewey’s Tragedy

A Hopeful Turned Fatal

Tricia Anne Dewey’s journey began in the shadows of domestic abuse and a painful opioid dependency that spanned her twenties. By age 41, she had achieved sobriety and sought a solution for lingering anxiety and insomnia. The promise of a “brain‑rewiring” drug, amplified by social‑media ads, seemed like a lifeline.

After a 20‑minute video call with a clinician listed on Better U’s roster, Dewey received a nasal spray kit. The instructions advised a single dose of 0.5 mg/kg, followed by a 30‑minute observation period—yet no on‑site medical staff were present. Within hours, Dewey experienced intense dissociation, a known acute side effect, and later suffered a cardiac arrhythmia that emergency responders attributed to ketamine‑induced hypertension.

Official records from the New York County Medical Examiner’s Office list the cause of death as “cardiopulmonary arrest secondary to ketamine toxicity.” The case underscores a broader trend: the National Center for Health Statistics recorded 112 ketamine‑related deaths between 2020 and 2023, a 68 % increase from the previous five‑year span.

Family members filed a wrongful‑death suit alleging negligence in the provider’s failure to conduct a thorough cardiac risk assessment. Legal experts note that, because ketamine is classified as a Schedule III substance, providers must adhere to the same prescribing standards as any controlled medication—a standard Better U arguably did not meet.

Public health advocates point to Dewey’s story as a cautionary tale about the perils of unregulated access. The stat_card below captures the rise in reported ketamine‑related fatalities over the past four years.

Can Policy and Science Align to Safeguard Patients?

Bridging the Gap Between Innovation and Safety

The trajectory of ketamine telehealth suggests that without decisive policy action, the market will continue to outpace safety mechanisms. Legislators are beginning to respond. In 2024, the Senate introduced the Psychedelic Telehealth Safety Act, which would require all telehealth platforms prescribing controlled substances to register with the DEA, implement a standardized psychiatric assessment, and report adverse events to the FDA’s MedWatch system.

Parallel to legislative efforts, professional societies are crafting clinical guidelines. The American Psychiatric Association released a draft position paper in early 2024 recommending that at‑home ketamine administration be limited to patients who have completed at least two supervised in‑clinic sessions and have documented remission of depressive symptoms.

From an industry standpoint, several telehealth firms have voluntarily adopted a “Safety First” framework, incorporating remote vital‑sign monitoring via wearable devices and mandatory 24‑hour clinician hotlines. Early data from a pilot program at a Midwest telehealth startup showed a 22 % reduction in adverse‑event reporting after implementing continuous pulse‑oximetry.

To measure progress, policymakers can track key performance indicators. The bullet_kpi chart below outlines five metrics that could serve as benchmarks for a safer ketamine telehealth ecosystem.